Background: Malaria diagnosis is vital to efficient control programmes and the recent advent of malaria rapid diagnostic tests (RDTs) provides a reliable and simple diagnostic method. However a characterization of the efficiency of these tests and the proteins they detect is needed to maximize RDT sensitivity.
Background
Rapid and reliable diagnosis is one of the key factors in promoting malaria control. The gold standard for malaria diagnosis remains the examination of Giemsa-stained smears by light microscopy. Whilst this standard has a good sensitivity and specificity and allows species and stage differentiation, it does require the expertise of a trained and experienced microscopist, is time-consuming (30 minutes per diagnostic) and requires equipment not always available or maintainable in remote areas. The 1990's have seen the advent of a new rapid diagnostic method, the immunochromatography-based malaria Rapid Diagnostic Tests (RDTs). These assays are fast (revealed in 15 minutes) and, for the most part, very simple to use. Moreover with the change of therapeutic practice towards relatively expensive artemisinin-based combination therapies [1] , a good diagnostic has become essential to limit inappropriate treatment and the development of resistance. Although the use of RDTs has spread, their reliability is still questioned in numerous studies [2, 3] . These assays detect one or several antigens, the most common are: histidine-rich protein-2 (HRP-2), aldolase and lactate dehydrogenase (pLDH).
Lactate dehydrogenase is an enzyme that catalyzes the inter-conversion of lactate into pyruvate. This enzyme is essential for energy production in Plasmodium [4] . The level of pLDH in the blood has been directly linked to the level of parasitaemia [5] .
The genetic diversity of HRP2 has been examined and partly linked to RDT detection sensitivity [6] , the genetic variability has also been assessed in aldolase, it has been ruled out as a possible cue for variation RDT sensitivity [7] . Here is the first study of Plasmodium LDH genetic variability as a possible cause of variation in sensitivity of RDTs.
Methods
A total of eight Plasmodium species (Plasmodium falciparum, Plasmodium vivax, Plasmodium. ovale, Plasmodium malariae, Plasmodium yoeli, Plasmodium chabaudi, Plasmodium berghei and Plasmodium. reichnowi), including the four human pathogens, from numerous origins ( Figure 1 ) were examined with a nested-PCR assay amplifying a 543 bp fragment: corresponding to the 57 to 237 amino acid position of the reference P. falciparum LDH coding sequence (pf13_0141). All field samples analysed were Worldwide distribution of the isolate sequenced in the study, grouped by species Figure 1 Worldwide distribution of the isolate sequenced in the study, grouped by species. One dot corresponds to one isolate, in red the malaria endemic area. diagnosed by microscopic examination and confirmed by PCR [8] and conserved from previous studies and approved at the time by respective National Ethics Committees. Two sets of PCR and nested primers were designed for this study based on the sequences available on GenBank (Table 1 ) one set use for P. vivax and P. falciparum, and the other for P. ovale and P. malariae.
Forty PCR cycle were undertaken using 94°C for 30 s, 55°C for 60 s and 72°C for 75 s; the same cycle was used for the nested-PCR but only repeated 35 times. Positive and negative controls were included in all amplification assays. The amplified products were purified using a Quiaquick PCR purification kit (QIAGEN, Valencia, CA) according to the manufacturer's recommendations, and sequenced using Big Dye Terminator kit v1.1 (Applied Biosystems, Foster City, CA) in an AbiPrism 3130 sequencing machine (Applied Biosystems, Foster City, CA).
Results
No variability was observed in P. falciparum (n = 49) with a homology of 100% between all newly sequenced sequences (named F). A single reference sequence on Gen-Bank (corresponding to the FCC1/HN strain) exhibited a different amino acid sequence (named F1). For P. vivax (n = 10), four different types of sequence were found, the mutations observed were all synonymous (named V); no geographic pattern was identified. P. malariae (n = 17) exhibited three different type of sequences, one for African and American isolates and the other two for the south-east Asian isolate and reference strain respectively. Those variations resulted in the same amino acid sequence (named M). P. ovale (n = 13) exhibited three different types of nucleotide sequences, leading to three different types of amino acid sequences (named O1, O2 and O3). P. berghei and P. yoeli sequences exhibited synonymous mutations (named Y). P. chabaudi exhibited a nucleotide sequence (named C).P. reichnowi and P. falciparum sequences exhibited synonymous mutations.
Interestingly a comparison of the sequences of different species reveals the existence of conserved regions and other very variable ones; this inter-specific variation is exhibited in Figure 2 . Table 2 gives details of the analysed isolates.
Discussion
Here is described, for the first time, the sequence variability of pLDH in the four human's species of malaria and four animal Plasmodium species and analysed them together with published sequences. The results indicate the existence of both variable and conserved regions in plasmodial lactate dehydrogenase.
The intra-specific geographic conservation of pLDH suggests that genetic variability may not be linked to disparities in sensitivities or specificities observed in the detection of P. falciparum [3] with anti-pan LDH antibodies. The falciparum-specific epitope detected by RDTs is probably situated in the inter-specific variable regions we have identified; whilst the pan-malarial epitope is more likely situated in a conserved region. However, Moody et al. [2] reported that one pan-specific monoclonal antibody used in a pLDH RDT has a lower affinity to P. malariae and P. ovale antigens, the attribution of this to a sequence divergence must not be neglected and should be further investigated.
Conclusion
The WHO states: "Rapid diagnostic tests (RDTs) offer the potential to provide accurate diagnosis to all at risk populations (...) The success of RDTs in malaria control will depend on good quality planning and implementation" [9] . Moreover a rapid diagnostic test needs to be reliable globally, to detect an antigen that mirrors accurately blood parasitaemia; therefore part of a good quality assurance is to monitor such factors. As part of this quality assurance, we have identified that an intra-specific genetic variability is not a significant factor in the variation of efficiency observed in rapid diagnostic tests in the detection of P. falciparum, P vivax and P. malariae, although it may explain the poor sensitivity to P. ovale [7] . Similar findings of low variability have been demonstrated for plasmodial aldolase another target antigen of MRDTs [10] despite a bad sensitivity in the dectection of P. ovale infection [11] in contrast to HRP2, a target antigen of P. falciparum with high variability affecting MRDT sensitivity. In this regard, pLDH offers advantages as a target antigen for diagnosis. 
